Glycoprotein IIb/IIIa inhibitors in the treatment of thromboembolic events related to endovascular treatment of cerebral aneurysms-systematic review and meta-analysis
Restricted accessReview articleFirst published online April, 2024
Glycoprotein IIb/IIIa inhibitors in the treatment of thromboembolic events related to endovascular treatment of cerebral aneurysms-systematic review and meta-analysis
Thromboembolism complication is considered the most common complication associated with the treatment of endovascular. This systematic review and meta-analysis aimed to assess the studies investigating the effect of glycoprotein IIb/IIIa inhibitor agents on thromboembolic complications during endovascular aneurysm coiling.
Materials and Methods
This systematic review investigated the outcome of the use of three glycoprotein IIb/IIIa inhibitor agents (ie abciximab, tirofiban, and eptifibatide) on the thromboembolic complications during endovascular aneurysm coiling. The electronic databases of PubMed, Web of Science, Scopus, and Medline were searched up to 25 June 2021, using the keywords “Abciximab,” “Tirofiban,” and “Eptifibatide” incombination with “Thromboembolism Complication,” “Aneurysms,” and “Endovascular Aneurysm Coiling.”
Results
A total of 21 articles were found to be eligible and included in this review. The rates of complete and partial recanalization were estimated to be 56% and 92% in patients who underwent abciximab and tirofiban therapy, respectively. Rupture aneurysms were found in the majority of patients. In general, the mortality rate of the patients treated for thromboembolic complications during endovascular treatment of cerebral aneurysms with glycoprotein IIb/IIIa inhibitors was found to be 4.8% (CI 95%:0.027–0.067; p < .005). The average remission rate in studies investigating thromboembolism was 91% (CI 95%:0.88–0.95, I2 : 65.65/p < .001).
Conclusion
Based on the obtained results, a higher mean rate of complete recanalization by eptifibatide was found in studies in which abciximab or tirofiban were used, compared to other mentioned agents. Moreover, the amount of hemorrhage was reported to be less after using tirofiban rather than abciximab.
AggourMPierotLKadziolkaK, et al.Abciximab treatment modalities for thromboembolic events related to aneurysm coiling. Neurosurgery2010; 67(suppl_2): ons503–508.
2.
SongJKNiimiYFernandezPM, et al.Thrombus formation during intracranial aneurysm coil placement: treatment with intra-arterial abciximab. AJNR Am J Neuroradiol2004; 25(7): 1147–1153.
3.
FriedmanJAPiepgrasDGPichelmannMA, et al.Small cerebral aneurysms presenting with symptoms other than rupture. Neurology2001; 57(7): 1212–1216.
4.
WiebersDOWhisnantJPHustonJ,3rdet al. International Study of Unruptured Intracranial Aneurysms Investigators.Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet2003; 362(9378): 103–110.
5.
International Study of Unruptured Intracranial Aneurysms Investigators. Unruptured intracranial aneurysms—risk of rupture and risks of surgical intervention. N Engl J Med1998; 339(24): 1725–1733.
6.
CognardCWeillACastaingsL, et al.Intracranial berry aneurysms: angiographic and clinical results after endovascular treatment. Radiology1998; 206(2): 499–510.
7.
WorkmanMJCloftHJTongFC, et al.Thrombus formation at the neck of cerebral aneurysms during treatment with Guglielmi detachable coils. AJNR Am J Neuroradiol2002; 23(9): 1568–1576.
8.
PelzDMLownieSPFoxAJ. Thromboembolic events associated with the treatment of cerebral aneurysms with Guglielmi detachable coils. AJNR Am J Neuroradiol1998; 19(8): 1541–1547.
9.
BizzarriFScollettaSTucciE, et al.Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg2001; 122(6): 1181–1185.
10.
JeongHWJinS-C. Intra-arterial infusion of a glycoprotein IIb/IIIa antagonist for the treatment of thromboembolism during coil embolization of intracranial aneurysm: a comparison of abciximab and tirofiban. AJNR Am J Neuroradiol2013; 34(8): 1621–1625.
11.
CronqvistMPierotLBoulinA, et al.Local intraarterial fibrinolysis of thromboemboli occurring during endovascular treatment of intracerebral aneurysm: a comparison of anatomic results and clinical outcome. AJNR Am J Neuroradiol1998; 19(1): 157–165.
12.
HahnelSSchellingerPDGutschalkA, et al.Local intra-arterial fibrinolysis of thromboemboli occurring during neuroendovascular procedures with recombinant tissue plasminogen activator. Stroke2003; 34(7): 1723–1728.
13.
FiorellaDAlbuquerqueFCHanP, et al.Strategies for the management of intraprocedural thromboembolic complications with abciximab (ReoPro). Neurosurgery2004; 54(5): 1089–1097; discussion 1097–1098.
14.
Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke2000; 31(3): 601–609.
15.
GreenSHigginsJ. Cochrane handbook for systematic reviews of interventions. London: Cochrane, 2005.
16.
HigginsJ. Cochrane handbook for systematic reviews of interventions. London: The Cochrane Collaboration, 2011. https://www.cochrane-handbook.org
17.
MounayerCPiotinMBaldiS, et al.Intraarterial administration of abciximab for thromboembolic events occurring during aneurysm coil placement. AJNR Am J Neuroradiol2003; 24(10): 2039–2043.
18.
Martínez-PérezRLownieSPPelzD. Intra-arterial use of abciximab in thromboembolic complications associated with cerebral aneurysm coiling: the london ontario experience. World Neurosurg2017; 100: 342–350.
19.
JonesRGDavagnanamIColleyS, et al.Abciximab for treatment of thromboembolic complications during endovascular coiling of intracranial aneurysms. AJNR Am J Neuroradiol2008; 29(10): 1925–1929.
20.
GrallaJRennieATMCorkillRA, et al.Abciximab for thrombolysis during intracranial aneurysm coiling. Neuroradiology2008; 50(12): 1041–1047.
21.
LinfanteIEtezadiVAndreoneV, et al.Intra-arterial abciximab for the treatment of thrombus formation during coil embolization of intracranial aneurysms. J Neurointerv Surg2010; 2(2): 135–138.
22.
RiesTSiemonsenSGrzyskaU, et al.Abciximab is a safe rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization: single center experience in 42 cases and review of the literature. Stroke2009; 40(5): 1750–1757.
23.
ParkJHKimJESheenSH, et al.Intraarterial abciximab for treatment of thromboembolism during coil embolization of intracranial aneurysms: outcome and fatal hemorrhagic complications. J Neurosurg2008; 108(3): 450–457.
24.
VelatGJBurryMVEskiogluE, et al.The use of abciximab in the treatment of acute cerebral thromboembolic events during neuroendovascular procedures. Surg Neurol2006; 65(4): 352–358, discussion 358–359.
25.
AvivRIO’NeillRPatelMC, et al.Abciximab in patients with ruptured intracranial aneurysms. AJNR Am J Neuroradiol2005; 26(7): 1744–1750.
26.
GentricJ-CBrissonJBatistaAL, et al.Safety of Abciximab injection during endovascular treatment of ruptured aneurysms. Interv Neuroradiol2015; 21(3): 332–336.
27.
BrueningRMueller-SchunkSMorhardD, et al.Intraprocedural thrombus formation during coil placement in ruptured intracranial aneurysms: treatment with systemic application of the glycoprotein IIb/IIIa antagonist tirofiban. AJNR Am J Neuroradiol2006; 27(6): 1326–1331.
28.
KangH-SKwonBJRohHG, et al.Intra-arterial tirofiban infusion for thromboembolism during endovascular treatment of intracranial aneurysms. Neurosurgery2008; 63(2): 230–237; discussion 237–238.
29.
ChoYDLeeJYSeoJH, et al.Intra-arterial tirofiban infusion for thromboembolic complication during coil embolization of ruptured intracranial aneurysms. Eur J Radiol2012; 81(10): 2833–2838.
30.
KimSHKimTGKongMH. Intra-arterial and intravenous tirofiban infusion for thromboembolism during endovascular coil embolization of cerebral aneurysm. J Korean Neurosurg Soc2017; 60(5): 518–526.
31.
RamakrishnanPYooAJRabinovJD, et al.Intra-arterial eptifibatide in the management of thromboembolism during endovascular treatment of intracranial aneurysms: case series and a review of the literature. Interv Neurol2013; 2(1): 19–29.
32.
KatsaridisVPapagiannakiCSkouliosN, et al.Local intra-arterial eptifibatide for intraoperative vessel thrombosis during aneurysm coiling. AJNR Am J Neuroradiol2008; 29(7): 1414–1417.
33.
WalshRDBarrettKMAguilarMI, et al.Intracranial hemorrhage following neuroendovascular procedures with abciximab is associated with high mortality: a multicenter series. Neurocrit Care2011; 15(1): 85–95.
34.
EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med1997; 336(24): 1689–1696.
35.
MascitelliJROermannEKDe LeacyRA, et al.Predictors of treatment failure following coil embolization of intracranial aneurysms. J Clin Neurosci2015; 22(8): 1275–1281.
36.
YiH-JGuptaRJovinTG, et al.Initial experience with the use of intravenous eptifibatide bolus during endovascular treatment of intracranial aneurysms. AJNR Am J Neuroradiol2006; 27(9): 1856–1860.
37.
ColletJPMontalescotGLestyC, et al.A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res2002; 90(4): 428–434.
38.
KwonO-KLeeKJHanMH, et al.Intraarterially administered abciximab as an adjuvant thrombolytic therapy: report of three cases. AJNR Am J Neuroradiol2002; 23(3): 447–451.
39.
DuncanICFouriePA. Catheter-directed intra-arterial abciximab administration for acute thrombotic occlusions during neurointerventional procedures. Interv Neuroradiol2002; 8(2): 159–168.
40.
PagolaJRiboMAlvarez‐SabinJ, et al.Thrombolysis in anterior versus posterior circulation strokes: timing of recanalization, ischemic tolerance, and other differences. J Neuroimaging2011; 21(2): 108–112.
41.
MorrisP. Interventional and endovascular therapy of the nervous system: a practical guide. Berlin, Germany: Springer Science and Business Media, 2002.
42.
HarderSKlinkhardtUAlvarezJM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet2004; 43(14): 963–981.
43.
HoDSWWangYChuiM, et al.Intracarotid abciximab injection to abort impending ischemic stroke during carotid angioplasty. Cerebrovasc Dis2001; 11(4): 300–304.
44.
KittusamyPKKoenigsbergRAMcCormickDJ. Abciximab for the treatment of acute distal embolization associated with internal carotid artery angioplasty. Catheter Cardiovasc Interv2001; 54(2): 221–233.
45.
CollerBS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost2001; 86(07): 427–443.
46.
AkkerhuisKMDeckersJWLincoffAM, et al.Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. Jama2001; 286(1): 78–82.
47.
NgPPPhatourosCCKhangureMS. Use of glycoprotein IIb-IIIa inhibitor for a thromboembolic complication during Guglielmi detachable coil treatment of an acutely ruptured aneurysm. AJNR Am J Neuroradiol2001; 22(9): 1761–1763.
48.
LempertTEMalekAMHalbachVV, et al.Rescue treatment of acute parent vessel thrombosis with glycoprotein IIb/IIIa inhibitor during GDC coil embolization. Stroke1999; 30: 693–695.
49.
TopolEJFergusonJJWeismanHF, et al.Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. Jama1997; 278(6): 479–484.
50.
TopolEJMoliternoDJHerrmannHCet al. TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med2001; 344(25): 1888–1894.
51.
HerrmannHCSwierkoszTAKapoorS, et al.Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non–Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol2002; 89(11): 1293–1297.
52.
MangiaficoSCelleriniMNenciniP, et al.Intravenous tirofiban with intra-arterial urokinase and mechanical thrombolysis in stroke: preliminary experience in 11 cases. Stroke2005; 36(10): 2154–2158.
